Inhaled biopharmaceutical drug development: nonclinical considerations and case studies

References

• Alavi F. (2004). Pharmacology/toxicology review and evaluation: Exubera® (inhaled insulin). Food and Drug Administration Center for Drug Evaluation and Research. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B1_02_04-FDA-ClinPharm-Toxicology.pdf. [Last accessed: 11 Feb 2013]
   Google Scholar
• Alton EW, Stern M, Farley R, et al. (1999). Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 20:947–54
   Google Scholar
• Alton EWFW, Ashby D, Boyd AC, et al. (2012). Update on the UK CF gene therapy consortium multidose, non-viral, gene therapy trial. Pediat Pulmonol 47: abstract 245. Available from: http://www.cfgenetherapy.org.uk/publications/AltonNACFC2012.html. [Last accessed: 11 Feb 2013]
   Google Scholar
• Baker, MP, Carr FJ. (2010). Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics. Curr Drug Saf 5:308–13
   PubMedGoogle Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. (2010). Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 4:314–22
   Google Scholar
• Becker RH, Sha S, Frick AD, Fountaine RJ. (2006). The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 29:277–82
   PubMed Web of Science ®Google Scholar
• Birchall JC, Kellaway IW, Gumbleton M. (2000). Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int J Pharm 197:221–31
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA. (2006). Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 58:1106–18
   PubMed Web of Science ®Google Scholar
• Brain JD. (2007). Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol Ther 9:S4–S15
   Web of Science ®Google Scholar
• Burger JL. (2008). Stabilising formulations for inhalable powders of live attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 21:25–34
   PubMed Web of Science ®Google Scholar
• Cavagnaro J. (2008). The principles of the ICH S6 and the case-by-case approach. In: Cavagnaro J, ed. Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. NJ: John Wiley & Sons, 45–65
   Google Scholar
• Cheng YS, Bowen L, Rando RJ, et al. (2010). Exposing animals to oxidant gases nose only vs. whole body. Proc Am Thorac Soc 7:264–8
   PubMedGoogle Scholar
• Clarke J, Hurst C, Martin P, et al. (2008). Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate? Regul Toxicol Pharmacol 50:2–22
   PubMed Web of Science ®Google Scholar
• Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and the Council on the Community code relating to medicinal products for human use. Official Journal L159, 27.06.2003, p 46
   Google Scholar
• Cosenza ME. (2008). Implementation of the ICH S6: US perspective. In: Cavagnaro J, ed. Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. NJ: John Wiley & Sons, 111–21
   Google Scholar
• Cooper AE, Ferguson D, Grime K. (2012). Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab 13:457–73
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29–38
   PubMed Web of Science ®Google Scholar
• De Swart RL, Kuiken T, Fernandez-de CJ, et al. (2006). Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 24:6424–36
   PubMed Web of Science ®Google Scholar
• Driscoll KE, Costa DL, Hatch G, et al. (2000). Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicol Sci 55:24–35
   PubMed Web of Science ®Google Scholar
• Eastman SJ, Tousignant JD, Lukason MJ, et al. (1997). Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes. Hum Gene Ther 10:313–22
   Google Scholar
• Exubera. (2006). US product insert, NDA 21-868 Version date: 2006-01-27. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021868lbl.pdf. [Last accessed: 7 Nov 2012]
   Google Scholar
• FDA. (1993). Summary basis of approval for dornase alfa, recombinant pulmozyme inhalation solution. Washington, DC: FDA
   Google Scholar
• Fernandez-de CJ, Kumate-Rodriguez J, Sepulveda J, et al. (1997). Measles vaccination by the aerosol method in Mexico. Salud Publica Mex 39:53–60
   PubMed Web of Science ®Google Scholar
• Fineberg SE, Kawabata T, Finco-Kent D, et al. (2005). Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. J Clin Endocrinol Metab 90:3287–94
   PubMed Web of Science ®Google Scholar
• Forbes B, Asgharian B, Dailey LA, et al. (2011). Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev 63:69–87
   PubMed Web of Science ®Google Scholar
• Forster R, Appleqvist T, Brown D, et al. (2008). Pulmonary delivery of measles vaccine: non-human primate safety study 2008: annual meeting of SOT, Seattle. Toxicologist 2297:473 (abstract)
   Google Scholar
• Freemantle N, Blonde L, Duhot D, et al. (2005). Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28:427–8
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Uster P, Cow G, McDonald P. (2001). Four week repeat dose inhalation safety of insulin in dogs. J Aerosol Med 14:379–421 (abstract)
   Google Scholar
• Green, JD. (1994). Pharmaco-toxicological expert report: Pulmozyme™, rhDNase, Genentech, Inc. Hum Exp Toxicol 13:SI–S42
   Google Scholar
• Griesenbach U, Alton EWFW. (2009). Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 61:128–39
   PubMed Web of Science ®Google Scholar
• Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A, et al. (2011). Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Adv Drug Deliv Rev 63:110–8
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Greco M, Laurie X, et al. (2010). Measles aerosol vaccine project. Proc Vaccinol 2:147–50
   Google Scholar
• Himmelmann A, Jendle J, Mellén A, et al. (2003). The impact of smoking on inhaled insulin. Diabetes Care 26:677–82
   PubMed Web of Science ®Google Scholar
• Hyde SC, Pringle IA, Abdullah S, et al. (2008). CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26:549–51
   PubMed Web of Science ®Google Scholar
• Kim KJ, Malik AB. (2003). Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol 284:L247–59
   PubMed Web of Science ®Google Scholar
• Kohlmeier JE, Woodland DL. (2009). Immunity to respiratory viruses. Annu Rev Immunol 27:61–82
   PubMed Web of Science ®Google Scholar
• Lam AP, Dean DA. (2008). Cyclic stretch-induced nuclear localization of transcription factors results in increased nuclear targeting of plasmids in alveolar epithelial cells. J Gene Med 10:668–78
   PubMed Web of Science ®Google Scholar
• Leong LK. (2012). Refinements in inhaled drug delivery enhances growth prospects as global markets emerge. Available from: http://www.pharmaasia.com/article/refinements-in-inhaled-drug-delivery-enhances-growth-prospects-as-global-markets-emerge/9367. [Last accessed: 28 Apr 2012]
   Google Scholar
• Legakis G, Causton B, Zhu J, et al. (2011). Strain-specific differences in pulmonary gene transfer efficiency: relevance for toxicology studies in mice (abstract). Available from: http://www.cfgenetherapy.org.uk/publications/LegakisASGT2011.html. [Last accessed: 11 Feb 2013]
   Google Scholar
• Mack P, Horvath K, Garcia A, et al. (2012). Particle engineering for inhalation formulation and delivery of biotherapeutics. Inhalation Available from: http://www.inhalationmag.com/(Content/getArticle.aspx?ItemID=0992431a-53ae-4828-b89f-210da3aa4c32&AuthorID=cc2fbfff-7bd0-45e1-a871-87fabe3d2912&Author=Mack%2c+Peter). [Last accessed: 11 Feb 2013]
   Google Scholar
• Mastrandea LD. (2010). Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag 3:47–58
   Google Scholar
• Martin PL. (2008). Reproductive toxicity testing for biopharmaceuticals. In: Cavagnaro J, ed. Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. NJ: John Wiley & Sons, 357–77
   Google Scholar
• McConnell WR, Finch GL, Elwell MR, et al. (2006). Toxicological investigations on inhaled insulin (abstract). Society of Toxicology Annual Meeting; 2006 Mar 5–9; San Diego, CA
   Google Scholar
• McLachlan G, Davidson H, Holder E, et al. (2011). Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther 18:996–1005
   PubMed Web of Science ®Google Scholar
• Moore S, Goodway R, Cracknell S, Paul G. (2012). Capsule based aerosol generation – test article conservation during the conduct of in vivo lead optimisation respiratory safety assessment studies (abstract). Presented at the AIT; 2012 Oct 16–18; Edinburgh, UK
   Google Scholar
• Moss RB, Milla C, Colombo J, et al. (2007). Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 18:726–32
   PubMed Web of Science ®Google Scholar
• Patton JS, Brain JD, Davies LA, et al. (2010). The particle has landed – characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv 23:S71–87
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67–74
   PubMed Web of Science ®Google Scholar
• Patton JS, Platz RM. (1992). Routes of delivery: case studies. “Pulmonary delivery of peptides and proteins for systemic action”. Adv Drug Deliv Rev 8:179–96
   Web of Science ®Google Scholar
• Perricone MA, Morris JE, Pavelka K, et al. (2001). Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther 12:1383–94
   PubMed Web of Science ®Google Scholar
• Ponce R, Abad L, Amaravadi L, et al. (2009). Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54:164–82
   PubMed Web of Science ®Google Scholar
• Praetor A, Ellinger I, Hunziker W. (1999). Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells. J Cell Sci 112:2291–9
   PubMed Web of Science ®Google Scholar
• Rader RA. (2005). What is a biopharmaceutical: part 1: (bio)technology-based definitions. BioExecutive Int March:60–5
   Google Scholar
• Randall TD. (2010). Bronchus-associated lymphoid tissue (BALT) structure and function. Adv Immunol 107:187–241
   PubMed Web of Science ®Google Scholar
• Rave K, de la Peña A, Tibaldi FS, et al. (2007). AIR inhaled insulin in subjects with chronic obstructive pulmonary disease. Diabetes Care 30:1777–82
   PubMed Web of Science ®Google Scholar
• Rudolph C, Müller RH, Rosenecker J. (2002). Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency. J Gene Med 4:66–74
   PubMed Web of Science ®Google Scholar
• Sabin AB. (1983). Immunization against measles by aerosol. Rev Infect Dis 5:514–23
   PubMedGoogle Scholar
• Sabin AB, Flores Arechiga A, Fernández de Castro J, et al. (1984). Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 251:2363–71
   PubMed Web of Science ®Google Scholar
• Serabian MA, Huang Y. (2008). Preclinical safety evaluation of biopharmaceuticals. In: Cavagnaro J. ed. Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. NJ: John Wiley & Sons, 45–65
   Google Scholar
• Shoyele SA, Cawthorne S. (2006). Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Delivery Rev 58:1009–29
   PubMed Web of Science ®Google Scholar
• Siekmeier R, Scheuch G. (2008a). Systemic treatment by inhalation of macromolecules – principles, problems and examples. J Physiol Pharmacol 59:53–79
   PubMed Web of Science ®Google Scholar
• Siekmeier R, Scheuch G. (2008b). Inhaled insulin – does it become reality? J Physiol Pharmacol 59:81–113
   PubMed Web of Science ®Google Scholar
• Valdespino-Gomez JL, de Lourdes Garcia-Garcia M, Fernandez-de-Castro J, et al. (2006). Measles aerosol vaccination. Curr Top Microbiol Immunol 304:165–93
   PubMed Web of Science ®Google Scholar
• Vick A, Wolff R, Koester A, et al. (2007). A 6-month inhalation study to characterize the toxicity, pharmacokinetics, and pharmacodynamics of human insulin inhalation powder (HIIP) in Beagle dogs. J Aerosol Med 20:112–26
   PubMedGoogle Scholar
• Wan F, Møller EH, Yang M, Jørgensen L. (2012). Formulation technologies to overcome unfavourable properties of peptides and proteins for pulmonary delivery. Drug Discover Today 9:e141–6
   Google Scholar
• Wise S, Chien J, Yeo K, Richardson C. (2006). Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly--Dura inhaled insulin system. Diabet Med 23:510–15
   PubMed Web of Science ®Google Scholar
• Wolff RK. (1998). Safety of inhaled proteins for therapeutic use. J Aerosol Med 11:197–219
   PubMedGoogle Scholar
• Wolzt M, de la Pena A, Berclaz PY, et al. (2008). AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, gluco-dynamics and pulmonary function in asthma. Diabetes Care 31:735–40
   PubMed Web of Science ®Google Scholar
• Yew NS, Wang KX, Przybylska M, et al. (1999). Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 10:223–34
   PubMed Web of Science ®Google Scholar